Clinical Trials Logo

Clinical Trial Summary

Introduction: Non-CF, non-PCD bronchiectasis in children is a chronic, suppurative lung disease diagnosed by high resolution computed tomography (HRCT) imaging of the lungs. Spirometry can be abnormal in bronchiectasis but has been shown to be insensitive to early disease in other related conditions such as cystic fibrosis. Lung clearance index (LCI) could have a role in assessment of the disease. Lung clearance index is calculated from multiple breath washout tests. There are limited data on the normative values expected using some devices, in a range of ages, and between ethnic groups. The investigators aim to establish normative values in children aged between 6 years and 12 years, to investigate differences between ethnic groups, and to establish the relationship between lung clearance index and other measures of disease in children with bronchiectasis. Methods: Healthy children will be recruited from a range of settings and reviewed to ensure no previous lung disease. Children with bronchiectasis diagnosed on HRCT will be recruited from the outpatient service of Birmingham Children's Hospital. All participants will perform lung function tests including LCI and spirometry. Basic demographic data was collected.


Clinical Trial Description

Rationale / Hypothesis: Hypothesis 1 Having established normative ranges helps support interpretation of lung function testing which is key to their value as an investigation. With LCI, it is important to understand the difference that may be expected between children of different ethnic backgrounds (as demonstrated with other, non-LCI measures of lung function, where important differences between different ethnic groups has been found). LCI is calculated from an internally adjusted measure of an individual subject's lung volume, therefore potentially negating inherent differences in ethnic variation. Therefore we hypothesize that there are no differences in LCI in healthy children from differing ethnic backgrounds. Evidence supporting this hypothesis is not only of intellectual value, but it would also allow clinicians to confidently interpret a range of LCI readings using globally acquired normal values. Should the data not support the hypothesis, an important direction for future research would be established. Hypothesis 2 LCI has been demonstrated to detect small differences in lung function and correlates well with CT imaging in some disease states. There is a paucity of data in its use in its lung disease outside of CF. Current availability of easy to use, repeatable and reliable devices allows LCI to be measured in the clinic setting (Downing et al. 2016). Understanding the relationship between CT changes and LCI in younger children with lung disease, would allow a non-invasive investigation (LCI) to be used to guide care and monitor treatment. In order to understand how LCI changes, we also intend to determine how LCI varies in children with Non-CF, Non-PCD Bronchiectasis over a prolonged period of time. The investigators hypothesize that in younger children with Non-CF, Non-PCD Bronchiectasis and evidence of milder disease on CT, LCI is a more sensitive disease marker than FEV1, and varies over time. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05989360
Study type Interventional
Source Birmingham Women's and Children's NHS Foundation Trust
Contact
Status Completed
Phase N/A
Start date March 11, 2020
Completion date September 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Recruiting NCT06093191 - Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis Phase 4
Recruiting NCT06393257 - Airway Clearance Technique of Oscillation and Lung Expansion in Bronchiectasis N/A
Not yet recruiting NCT04509661 - Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation Phase 4
Recruiting NCT06017739 - Expiratory Flow Accelerator (Efa) vs Efa + High Flow in Chronic COPD and Bronchiectasis N/A
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Recruiting NCT03715322 - Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa Phase 3
Recruiting NCT03696290 - Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis Phase 2
Not yet recruiting NCT05068518 - The Role of Airway Microbiota on Clinical Phenotypes and Disease Severity in Bronchiectasis
Recruiting NCT04658277 - Effect of Long Term Clarithromycin for Prevention of Exacerbations in Non-cystic Fibrosis Bronchiectasis in Asian Populations N/A
Completed NCT04744220 - Evaluation of the Effect of Yoga Training on Functional Capacity and Quality of Life in Patients With Bronchiectasis N/A
Completed NCT05764343 - The Effect of Immediate Smoking Cessation Interventions for Smokers With Chronic Airway Diseases N/A
Recruiting NCT05582798 - Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function Phase 4
Not yet recruiting NCT04987827 - Investigating the Clinical Features and Prognosis of Bronchiectasis Adult Patients
Recruiting NCT03791086 - The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping
Completed NCT04234789 - Predictors of Physical Activity Performance and Dynamic Hyperinflation in Patients With Bronchiectasis N/A
Recruiting NCT04865861 - The Characteristic of Airway Microbiome Profiling of COPD-bronchiectasis Overlap Patients and Its Association With Acute Exacerbation
Completed NCT04742270 - Home Airway Clearance in Patients With Bronchiectasis (Home-Care Bronchiectasis) N/A
Recruiting NCT05330637 - Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.
Completed NCT03125174 - Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls N/A